Background: Despite antiretroviral therapy (ART), HIV-1 persists in a stable latent reservoir, primarily in resting memory CD4+ T cells.To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed and tested both in vitro and in vivo. The next step is to eliminate the resting CD4+ T cells in which latent HIV-1 has been induced through virus-specific immune mechanisms including cytolytic T lymphocytes (CTL). However, the vast majority (>98%) of latent viruses in chronic patients carry CTL escape mutations that render the infected cells insensitive to CTLs directed at common epitopes, such as SL9 epitope in HLA-A2-positive patients.
Methods: To test whether CD8+ T cells from patients under ART are able to recognize and clear latent HIV-1, we generated patient-derived humanized mice using a recently reported mouse system named MISTRG. With humanization by knockin replacement of the Csf1, Csf2, Il3, Tpo and Sirpa genes in the Rag2-/-Il2rg-/- genetic background, MISTRG mice are highly permissive for human hematopoiesis and support the reconstitution of robust human lymphoid and myelomonocytic systems. We infected patient-derived humanized mice with primary HIV-1 isolates grown from resting CD4+ T cells of the same patient and then evaluated antiviral effect of autologous CD8+ T cells.
Results: MISTRG mice engrafted with HLA-A2-positive patient bone marrow CD34+ cells successfully developed human T-lymphocyte and monocyte/macrophage subsets, which were sufficient to support HIV-1 infection. In control mice or mice that received autologous patient CD8+ T cells pre-stimulated with the common epitope SL9, levels of plasma HIV-1 RNA and proviral DNA in PBMCs continued to increase from day 14 to day 29 after infection. In sharp contrast, 100- to 1,000-fold decreases in plasma HIV-1 RNA levels were observed in all mice that received patient CD8+ T cells pre-stimulated with the mixture of Gag peptides including unmutated epitopes.
Conclusions: Our results demonstrate that chronically infected patients retain a broad spectrum viral-specific CTL response which is sufficient to inhibit in vivo replication of HIV-1 isolated from latent reservoir. These results suggest that latent HIV-1 can be eliminated in chronically infected patients despite the overwhelming presence of CTL escape variants. Directing efficient CTL responses to unmutated viral epitopes is essential to the clearance of latent HIV-1.
Broad-spectrum cytotoxic T lymphocytes suppress in vivo infection of patient-derived humanized mice with autologous latent HIV-1.